Search Results 1051-1060 of 13928 for Assay

1. A Study To Assess LXH254 In Patients With Previously Treated Unresectable Or Metastatic BRAFV600 Or NRAS Mutant Melanoma - Mayo Clinic

   Documentation of BRAFV600 or NRAS mutation in tumor tissue prior to study treatment as determined by local assay agreed by Novartis or as determined by ...

2. A Pilot Study To Assess The Efficacy Of Rituximab Therapy In Treatment Resistant FSGS - Mayo Clinic

   The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental ...

3. Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Confirmed PD-L1-positive SCCHN by Ventana SP263 assay; WHO/ECOG performance status of 0 or 1; At least 1 measurable lesion at baseline; No prior exposure to ...

4. Team bios - Gut Microbiome Laboratory - Mayo Clinic Research

   She uses in vitro T-cell stimulation assay and gnotobiotic mouse models to investigate the relationship between the gut microbiome and cancer treatment ...

5. Proton Beam Or Intensity-Modulated Radiation Therapy In Preserving Brain Function In Patients With IDH Mutant Grade II Or III Glioma - Mayo Clinic

   ... assays performed in clinical laboratory improvement amendments (CLIA)-approved laboratories ... assay. Exclusion Criteria: Definitive clinical or radiologic ...

6. Publications - Aziza Nassar, M.D., M.P.H. - Mayo Clinic

   Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor ...

7. Immunotherapeutic Strategy to Treat Recurrent Respiratory Papillomatosis - Mayo Clinic

   Subjects diagnosed with the Human Immunodeficiency Virus (HIV), or who have tested positive for HIV, documented by any licensed ELISA assay and confirmed by ...

8. Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) - Mayo Clinic

   ... assay score (Oncotype RS>25, high risk Mammaprint, PAM-50, EndoPredict or ProSigna score). - Note: Eligibility requires primary tumor size ≥1.0 cm in ...

9. Screening Study For KIT D816V Mutated Mast Cell Disease In Select Populations - Mayo Clinic

   No more than 1 prior result of “not detected” was obtained using a high-sensitivity assay (LOD ≤ 0.03%) and. Baseline serum tryptase level is elevated ...

10. A Study Of IMO-2125 In Combination With Ipilimumab Versus Ipilimumab Alone In Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) - Mayo Clinic

    If subject BRAF mutation status is unknown, before randomization the subject must have BRAF testing performed using an approved assay method;; Patients with ...